ダウンロード数: 282
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
45_793.pdf | 738.41 kB | Adobe PDF | 見る/開く |
タイトル: | Poor-risk胚細胞腫瘍に対する末梢血幹細胞移植併用大量化学療法の検討 |
その他のタイトル: | Clinical study of high-dose chemotherapy with peripheral blood stem cell transplantation for poor-risk germ cell tumor |
著者: | 岡村, 菊美 弓場, 宏 水谷, 一夫 後藤, 百万 小野, 佳成 大島, 伸一 直江, 知樹 |
著者名の別形: | OKAMURA, Kikuo YUBA, Hiroshi MIZUTANI, Kazuo GOTOH, Momokazu ONO, Yoshinari OHSHIMA, Shinichi NAOE, Tomoki |
キーワード: | High-dose chemotherapy Poor-risk germ cell tumor Peripheral blood stem cell transplantation |
発行日: | Nov-1999 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 45 |
号: | 11 |
開始ページ: | 793 |
終了ページ: | 798 |
抄録: | 胚細胞腫瘍6例に末梢血幹細胞移植併用大量化学療法を施行した.2例が再発症例で, 3例が導入化学療法に抵抗性と判断され, 1例が残存腫瘍が切除不能の縦隔腫瘍症例であった.再発腫瘍の2例ではcPR, cCRが得られたが, 結局再発癌死した.抵抗性の2例においてpCRが得られ, 肺に残存した腫瘍は摘出しなかったが, 23ヵ月, 24ヵ月経過した現在も再発を認めていない.強化地固め療法として行った1例においても, 24ヵ月PRを続けている Between January 1997 and December 1998, six patients with germ cell tumor were treated with high-dose CEC: carboplatin (1, 500 mg/m2), etoposide (1, 200 mg/m2) and cyclophosphamide (100 mg/kg), followed by peripheral blood stem cell transplantation (PBSCT) at Nagoya University Hospital. Four patients received one cycle of high-dose CEC and two received two cycles. The reasons why the high-dose CEC was administered included: 1) refractory to the induction chemotherapy (AFP/beta-HCG elevated during the induction chemotherapy or prolonged half-life of each marker) in three patients, 2) relapse in two patients, and 3) consolidation in one with unresectable mediastinal residual tumor. There were no treatment-related deaths and grade 1 hepatotoxicity occurred in one (17%) patient. The median duration (range) from PBSCT until a granulocyte count of 500/microL and a platelet count of 50, 000/microL was 8.5 (8-11) and 11 (9-16) days, respectively. Of the six patients studied, 5 responded to the treatment; two achieved a complete response (CR) and three achieved a partial response (PR). One patient achieving a CR and two achieving a PR remained in complete remission after 23 to 24 months of follow-up, while the remaining patients with a CR, a PR and an incomplete response died of the disease. High-dose CEC could be administered without serious toxicity but the effectiveness of high-dose CEC for the poor-risk patients with germ cell tumor needs to be further investigated. |
URI: | http://hdl.handle.net/2433/114153 |
PubMed ID: | 10637746 |
出現コレクション: | Vol.45 No.11 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。